Shanghai Fosun Pharmaceutical (Group)
Market Cap
CN¥164.4b
Last Updated
2021/06/14 09:19 UTC
Data Sources
Company Financials +
Executive Summary
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More Details
Rewards
Risk Analysis
Snowflake Analysis
Established dividend payer with adequate balance sheet.
Similar Companies
Share Price & News
How has Shanghai Fosun Pharmaceutical (Group)'s share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 600196 is more volatile than 75% of CN stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 600196's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
Market Performance
7 Day Return
4.9%
600196
-1.7%
CN Pharmaceuticals
-0.6%
CN Market
1 Year Return
103.5%
600196
11.7%
CN Pharmaceuticals
27.0%
CN Market
Return vs Industry: 600196 exceeded the CN Pharmaceuticals industry which returned 12.6% over the past year.
Return vs Market: 600196 exceeded the CN Market which returned 26.2% over the past year.
Shareholder returns
| 600196 | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.9% | -1.7% | -0.6% |
| 30 Day | -3.4% | -0.6% | 4.1% |
| 90 Day | 70.4% | 11.7% | 7.5% |
| 1 Year | 105.0%103.5% | 12.7%11.7% | 28.8%27.0% |
| 3 Year | 62.0%57.2% | 38.9%33.8% | 44.0%37.1% |
| 5 Year | 283.7%261.6% | 65.4%56.7% | 36.7%27.8% |
Long-Term Price Volatility Vs. Market
How volatile is Shanghai Fosun Pharmaceutical (Group)'s share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Shanghai Fosun Pharmaceutical (Group) undervalued compared to its fair value and its price relative to the market?
44.48x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 600196 (CN¥67.88) is trading above our estimate of fair value (CN¥29.88)
Significantly Below Fair Value: 600196 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 600196 is poor value based on its PE Ratio (44.5x) compared to the CN Pharmaceuticals industry average (32.1x).
PE vs Market: 600196 is poor value based on its PE Ratio (44.5x) compared to the CN market (32.1x).
Price to Earnings Growth Ratio
PEG Ratio: 600196 is poor value based on its PEG Ratio (2.4x)
Price to Book Ratio
PB vs Industry: 600196 is overvalued based on its PB Ratio (4.6x) compared to the CN Pharmaceuticals industry average (2.8x).
Future Growth
How is Shanghai Fosun Pharmaceutical (Group) forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
18.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600196's forecast earnings growth (18.8% per year) is above the savings rate (3.3%).
Earnings vs Market: 600196's earnings (18.8% per year) are forecast to grow slower than the CN market (21.2% per year).
High Growth Earnings: 600196's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600196's revenue (10.7% per year) is forecast to grow slower than the CN market (17.2% per year).
High Growth Revenue: 600196's revenue (10.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600196's Return on Equity is forecast to be low in 3 years time (12.7%).
Past Performance
How has Shanghai Fosun Pharmaceutical (Group) performed over the past 5 years?
6.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 600196 has high quality earnings.
Growing Profit Margin: 600196's current net profit margins (12.1%) are higher than last year (11.5%).
Past Earnings Growth Analysis
Earnings Trend: 600196's earnings have grown by 6% per year over the past 5 years.
Accelerating Growth: 600196's earnings growth over the past year (23.4%) exceeds its 5-year average (6% per year).
Earnings vs Industry: 600196 earnings growth over the past year (23.4%) underperformed the Pharmaceuticals industry 24.9%.
Return on Equity
High ROE: 600196's Return on Equity (9.1%) is considered low.
Financial Health
How is Shanghai Fosun Pharmaceutical (Group)'s financial position?
Financial Position Analysis
Short Term Liabilities: 600196's short term assets (CN¥27.3B) exceed its short term liabilities (CN¥25.9B).
Long Term Liabilities: 600196's short term assets (CN¥27.3B) exceed its long term liabilities (CN¥13.7B).
Debt to Equity History and Analysis
Debt Level: 600196's debt to equity ratio (49.2%) is considered high.
Reducing Debt: 600196's debt to equity ratio has reduced from 55.8% to 49.2% over the past 5 years.
Debt Coverage: 600196's debt is not well covered by operating cash flow (12.7%).
Interest Coverage: 600196 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Shanghai Fosun Pharmaceutical (Group) current dividend yield, its reliability and sustainability?
0.63%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 600196's dividend (0.63%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).
High Dividend: 600196's dividend (0.63%) is low compared to the top 25% of dividend payers in the CN market (1.83%).
Stability and Growth of Payments
Stable Dividend: 600196's dividends per share have been stable in the past 10 years.
Growing Dividend: 600196's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (28.2%), 600196's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 600196's dividends in 3 years are forecast to be well covered by earnings (31.3% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.7yrs
Average management tenure
CEO
Yifang Wu (51 yo)
5yrs
Tenure
CN¥9,210,000
Compensation
Mr. Yifang Wu has been the Chief Executive Officer President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since June 7, 2016. He served as President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd....
CEO Compensation Analysis
Compensation vs Market: Yifang's total compensation ($USD1.44M) is above average for companies of similar size in the CN market ($USD397.17K).
Compensation vs Earnings: Yifang's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: 600196's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Board Members
Experienced Board: 600196's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Ticker: 600196
- Exchange: SHSE
- Founded: 1994
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥164.423b
- Shares outstanding: 2.56b
- Website: https://www.fosunpharma.com
Number of Employees
Location
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Building A
- No. 1289 Yishan Road
- Shanghai
- 200233
- China
Listings
Biography
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceut...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/06/14 09:19 |
| End of Day Share Price | 2021/06/11 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.